Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement.
Joseph
J
Jakas
D001709:Biotechnology / Q000331:legislation & jurisprudence*; D004059:Diffusion of Innovation; D004282:Documentation / Q000266:history / Q000379:methods*; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D035082:Federal Government; D033161:Government Regulation; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D033181:Information Dissemination / Q000331:legislation & jurisprudence* / Q000379:methods; D018973:Intellectual Property; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence*; D014481:United States; D014495:Universities / Q000331:legislation & jurisprudence
D016328:NF-kappa B